Mather Group LLC. Sells 802 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Mather Group LLC. cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,857 shares of the biopharmaceutical company’s stock after selling 802 shares during the period. Mather Group LLC.’s holdings in Gilead Sciences were worth $633,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. State Street Corp boosted its stake in shares of Gilead Sciences by 1.4% during the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock valued at $5,044,795,000 after purchasing an additional 841,776 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Gilead Sciences by 50.9% during the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after purchasing an additional 11,665,593 shares in the last quarter. FMR LLC boosted its stake in shares of Gilead Sciences by 79.4% during the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after purchasing an additional 14,680,161 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Gilead Sciences by 2.1% during the third quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock valued at $2,302,119,000 after purchasing an additional 574,421 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Gilead Sciences by 3.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 7,752,975 shares of the biopharmaceutical company’s stock valued at $650,009,000 after purchasing an additional 224,960 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on GILD shares. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Truist Financial raised their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research note on Friday, November 8th. JPMorgan Chase & Co. raised their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. UBS Group raised their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Finally, Robert W. Baird raised their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Gilead Sciences Trading Up 1.7 %

Shares of Gilead Sciences stock opened at $99.65 on Thursday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The firm has a fifty day moving average price of $92.71 and a 200 day moving average price of $86.32. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $100.51. The stock has a market cap of $124.19 billion, a PE ratio of 1,107.22, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the previous year, the company earned $2.29 earnings per share. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. Equities research analysts predict that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 572,824 shares of company stock valued at $53,611,715. Corporate insiders own 0.29% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.